Ivax Gets FDA OK Letter

Ivax ( IVX) Wednesday said it had received an approvable letter from the federal regulators for its asthma treatment.

The Miami-based biotech firm said the Food and Drug Administration had sent the letter regarding the company's new drug application for albuterol sulfate using a CFC-free propellant in its patented breath-activated aerosol inhaler.

Ivax's breath-activated aerosol inhaler is already in use in Europe. The device eliminates the need to coordinate the manual release of the medicine with its inhalation, which is required by standard metered dose inhalers.

The company previously received an approvable letter from the FDA on a separate NDA for an HFA formulation of albuterol in a standard metered dose inhaler.

Ivax shares fell 14 cents, or 0.6%, to $24.18.

Typically, companies resubmit an NDA after receipt of an approvable letter with the intention of answering all of the questions that need to be addressed prior to approval.

More from Stocks

REPLAY: Jim Cramer on How to Navigate the Stock Market Amid Tariff Worries

REPLAY: Jim Cramer on How to Navigate the Stock Market Amid Tariff Worries

Jim Cramer: 4 Stocks Could Get Throttled By a 'Knock Down Drag Out' With China

Jim Cramer: 4 Stocks Could Get Throttled By a 'Knock Down Drag Out' With China

3 Warren Buffett Stock Picks That Could Be Perfect for Your Retirement Portfolio

3 Warren Buffett Stock Picks That Could Be Perfect for Your Retirement Portfolio

50 Stocks That Could Be Shredded If a U.S. Trade War With China Ignites

50 Stocks That Could Be Shredded If a U.S. Trade War With China Ignites

Why Starbucks Latest Data Reveal Should Worry Investors

Why Starbucks Latest Data Reveal Should Worry Investors